Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX43 in Advanced Non-small Cell Lung Cancer
jRCT2021250022Phase 2Recruiting
- Sponsor
- Henlius
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label trial of HLX43 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Henlius. Primary endpoint: Objective response rate (ORR). Started Nov 2025; status: recruiting.
02
Drugs
HLX43
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2021250022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021250022.